BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.49, $0.29 better than the analyst estimate of $0.20. Revenue for the quarter came in at $646.2 million versus the consensus estimate of $639.26 million.

GUIDANCE:

BioMarin Pharma sees FY2024 EPS of $2.60-$2.80, versus the consensus of $2.83. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.82 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.